Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 2,948.1	$ 2,928.2	$ 8,232.2	$ 8,207.0
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	474.4	456.8	1,325.8	1,289.6
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	507.1	478.0	1,197.6	1,160.0
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	462.4	473.3	1,418.3	1,299.7
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	222.5	230.8	660.0	633.8
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	299.7	273.8	839.2	806.1
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	187.2	194.4	508.8	644.5
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	126.3	143.3	360.0	366.0
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	190.5	187.0	541.4	500.2
Oncology
Disaggregation of Revenue [Line Items]
Net sales	241.8	260.9	645.8	734.7
Immunology
Disaggregation of Revenue [Line Items]
Net sales	53.3	42.9	142.4	100.3
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	182.9	187.0	592.9	672.1
North America Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	181.8	155.5	484.0	426.4
North America Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	37.3	28.7	120.7	77.3
North America Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	284.9	308.5	890.4	805.3
North America Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	58.5	63.3	184.4	159.1
North America Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	41.8	30.0	121.0	94.9
North America Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	70.8	91.3	187.4	326.1
North America Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	33.2	38.2	87.8	77.6
North America Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	96.0	100.4	275.9	269.5
North America Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	171.4	196.1	470.8	567.8
North America Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	7.9	12.3	26.9	31.4
North America Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	45.2	64.3	174.0	199.6
Europe Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	211.5	214.3	631.0	619.3
Europe Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	197.2	179.0	320.1	299.7
Europe Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	103.1	98.2	362.3	327.9
Europe Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	125.6	126.2	372.7	358.6
Europe Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	166.2	147.9	465.6	434.9
Europe Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	80.1	68.9	231.7	208.0
Europe Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	72.8	75.8	215.0	217.7
Europe Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	60.5	60.5	180.6	165.3
Europe Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	30.4	22.0	71.2	59.9
Europe Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	35.2	20.3	88.3	41.3
Europe Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	41.2	32.8	142.2	198.1
Rest of World Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	81.1	87.0	210.8	243.9
Rest of World Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	272.6	270.3	756.8	783.0
Rest of World Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	74.4	66.6	165.6	166.5
Rest of World Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	38.4	41.3	102.9	116.1
Rest of World Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	91.7	95.9	252.6	276.3
Rest of World Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	36.3	34.2	89.7	110.4
Rest of World Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	20.3	29.3	57.2	70.7
Rest of World Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	34.0	26.1	84.9	65.4
Rest of World Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	40.0	42.8	103.8	107.0
Rest of World Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	10.2	10.3	27.2	27.6
Rest of World Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	96.5	89.9	276.7	274.4
Operating Segment | North America Segment
Disaggregation of Revenue [Line Items]
Net sales	1,028.8	1,088.6	3,023.3	3,035.0
Operating Segment | Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	1,123.8	1,045.9	3,080.7	2,930.7
Operating Segment | Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 795.5	$ 793.7	$ 2,128.2	$ 2,241.3